MARKET

PCRX

PCRX

Pacira BioSciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.80
+0.28
+0.49%
After Hours: 57.71 -0.09 -0.15% 16:12 07/10 EDT
OPEN
57.50
PREV CLOSE
57.52
HIGH
58.45
LOW
56.86
VOLUME
509.15K
TURNOVER
--
52 WEEK HIGH
58.45
52 WEEK LOW
27.46
MARKET CAP
2.43B
P/E (TTM)
-7225.0000
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PCRX stock price target is 59.79 with a high estimate of 85.00 and a low estimate of 44.00.

EPS

PCRX News

More
Did Hedge Funds Make The Right Call On Pacira Biosciences Inc (PCRX)?
Insider Monkey · 3h ago
The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 9) Affimed NV (NASDAQ: AFMD)
Benzinga · 1d ago
The Daily Biotech Pulse: FDA Nod For Osmotica, OptiNose Strikes Co-promotion Deal, Orphan Drug Designation For AnaptysBio
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8)
Benzinga · 2d ago
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7)
Benzinga · 3d ago
Pacira Bio prices upsized convertible debt offering
Seeking Alpha - Article · 3d ago
Pacira BioSciences, Inc. Announces Pricing of $350.0 Million Aggregate Principal Amount of 0.750% Convertible Senior Notes due 2025
GlobeNewswire · 4d ago
Pacira BioSciences under pressure on preliminary Q2 results
Seeking Alpha - Article · 5d ago
Pacira BioSciences, Inc. Announces Proposed Offering of $300.0 Million Aggregate Principal Amount of Convertible Senior Notes
GlobeNewswire · 5d ago

Industry

Pharmaceuticals
-0.31%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About PCRX

Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
More

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.